Business context and reporting period
Repro Med Systems, Inc. (the filing registrant; now identified in the request as KORU Medical Systems, Inc.) filed this Form 10-K for the fiscal year ended February 28, 2015. It designs and sells medical devices, principally the FREEDOM60 infusion system and related needle sets, and RES-Q-VAC portable suction products. Infusion products represented 95.1% of gross sales, up from 91.7% in fiscal 2014.
Financial performance and liquidity
| Metric | FY2015 | FY2014 |
|---|---|---|
| Net sales | $11.245 million | $8.699 million |
| Gross profit / margin | $6.688 million / 59.5% | $5.310 million / 61.0% |
| Operating income | $1.147 million | $1.008 million |
| Net income / diluted EPS | $753,117 / $0.02 | $703,429 / $0.02 |
| Operating cash flow | $826,099 | $954,388 |
| Investing cash flow | ($744,981) | ($218,005) |
At year-end, cash and cash equivalents were $2.557 million, certificates of deposit were $260,000, and current assets and current liabilities were $5.908 million and $692,000, respectively. Total liabilities were $1.008 million; the former related-party loan had been repaid in May 2013, and the filing reports no outstanding long-term debt. The company reported positive operating cash flow and said available cash and expected operating cash generation should fund operations for the next 12 months.
Changes versus the prior year
- Sales grew 29.3%: domestic sales rose 30.3% and international sales 25.0%, driven primarily by infusion products and subcutaneous immunoglobulin (SCIG) applications.
- Gross profit increased 25.9%, but gross margin declined 1.5 percentage points to 59.5%, reflecting higher production labor and raw-material costs and a less profitable product mix.
- SG&A rose 24.3% to $4.788 million; R&D more than doubled to $468,154. Net income increased 7.1%, slower than sales growth, with higher expenses and a $77,966 foreign-exchange loss among the offsets.
- Operating cash flow fell to $826,099, in part because inventory increased by about $408,000. Investing outflows rose to $744,981, mainly for equipment, tooling, a clean-room installation, and patent costs.
- The company issued 1 million shares to Horton Capital for net proceeds of $273,000 and issued warrants to buy another 1 million shares at $0.45 per share. Shares outstanding increased during the year.
Outlook, risks and unusual items
Management anticipated continued sales growth as the SCIG market develops and cited potential applications in antibiotics, chemotherapy, and pain treatment. The FreedomEdge, a smaller syringe pump, was introduced in March 2015; the filing gives no quantified sales or earnings guidance and cautions that new-product development may not yield commercial success. Management also pointed to possible expansion of home infusion and a 2015 Medicare home-infusion bill, whose passage and impact were uncertain.
- Customer and channel concentration: one major customer generated approximately 52.9% of gross product revenue, versus 39.9% in FY2014; most sales were through distributors. The filing identifies a distributor representing approximately 53% of total revenue.
- Reimbursement, regulatory, competitive, supply, market-acceptance, financing, and key-personnel risks could affect results. Raw-material cost increases may not be recoverable through pricing.
- A competitor patent dispute involving the company’s needle sets remained in discovery; the company said it considered counterclaims meritless.
- The company recorded a $77,966 foreign-currency loss, largely associated with the euro’s decline. It also reported related-party arrangements, including aircraft leasing and a building lease involving directors or affiliates.
- The prior auditor resigned in October 2014; a successor audited FY2015 and issued an unqualified opinion. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not attest to internal controls.
Important facts for investors to verify
- Whether the high dependence on one customer and distributor persists, and the terms and continuity of those relationships.
- Whether sales growth converts into improved margins and cash generation, given rising inventory and investment needs.
- Current Medicare reimbursement rules and any changes in home-infusion coverage or product eligibility.
- FreedomEdge commercial uptake, required regulatory clearances, and the economics of expanding new applications and markets.
- Developments in the competitor litigation, foreign-exchange exposure, and the potential dilution from outstanding warrants and share-based compensation.